<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02460380</url>
  </required_header>
  <id_info>
    <org_study_id>2013-06-03</org_study_id>
    <nct_id>NCT02460380</nct_id>
  </id_info>
  <brief_title>The Effects of Vitamin D on Angiogenic Factors in Women With Polycystic Ovary Syndrome</brief_title>
  <official_title>The Effects of Vitamin D Supplementation on Transforming Growth Factor-beta1 and Vascular Endothelial Growth Factor in Vitamin D-Deficient Women With Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimonides Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic Ovary Syndrome (PCOS) affects 5 to 10% of women of reproductive age. It is
      characterized by a cluster of hyperandrogenism, hyperinsulinemia, menstrual dysfunction,
      hirsutism and infertility. Although the pathogenesis of PCOS is unknown, accumulating
      evidence suggests that the dysregulation of some angiogenic factors, such as transforming
      growth factor-β (TGF-β) and vascular endothelial growth factor (VEGF), may be implicated.
      TGF-βs and VEGF exert a diverse range of biological functions regulating cell proliferation,
      angiogenesis, fibroblast activation and tissue fibrosis. PCOS ovaries show all the hallmarks
      of TGF-β and VEGF upregulation, including increased collagen deposition in ovarian stroma and
      theca, supported by increased vascularity. Consistent with this, The investigators recently
      showed that TGF-β1 is increased in serum of PCOS women while its circulating receptor soluble
      endoglin (sENG) is decreased, resulting in greater TGF-β1 bioavailability. Furthermore, it
      has been shown that women with PCOS have increased VEGF levels in the serum and/or follicular
      fluid. PCOS patients also have decreased vitamin D levels, and vitamin D treatment has been
      previously shown to improve various clinical parameters in PCOS women, including glucose
      intolerance, hypertension and androgen levels. Interestingly, vitamin D has been shown to
      decrease TGF-β1 and VEGF levels in several diseases, including myelofibrosis and various
      human cancer cells. Therefore, the investigators hypothesize that vitamin D treatment of PCOS
      women will result in a decrease of serum TGF-β1 levels and/or VEGF levels concomitant with
      improvement in clinical disease parameters. In addition, the investigators hypothesize that
      improvement in clinical disease parameters will correlate with changes in serum VEGF levels
      and TGF-β1 bioavailability. Our aim in the present study is to investigate the effects of
      vitamin D treatment on serum VEGF and TGF-β1/sENG levels in PCOS women, and assess whether
      changes in these angiogenic factors following vitamin D treatment correlate with clinical
      disease in these women. For this end, PCOS patients who are vitamin D-deficient will be
      treated with vitamin D and their serum levels of VEGF, TGF-β1 and its sENG receptor will be
      measured before and after treatment. In addition, clinical disease parameters will be
      recorded before and 4 months after treatment, including serum glucose and insulin levels,
      serum androgen levels, and blood pressure.

      The proposed study aims to identify a putative link between vitamin D, VEGF, and TGF-β1 in
      the context of PCOS, and provide a novel molecular explanation for the beneficial clinical
      effects of vitamin D on PCOS patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, single blind, placebo-controlled trial to evaluate the effect of
      vitamin D on vitamin D-deficient women with PCOS. 93 reproductive-aged women diagnosed with
      PCOS presenting to Maimonides Medical Center for annual check-up between October 2013 and
      March 2015 were screened for vitamin D deficiency (defined as 25 hydroxy-vitaminD [25OH-D]
      levels &lt;20 ng/mL). All participants signed the informed consent and the study was approved by
      the international review board (IRB) of Maimonides Medical Center. PCOS was diagnosed
      according to the Rotterdam Consensus (ESHRE/ASRM criteria), i.e. the presence of two of three
      criteria: oligo- or anovulation, signs of clinical hyperandrogenism, and/or biochemical signs
      of hyperandrogenism and polycystic ovaries on ultrasonography after exclusion of specific
      identifiable disorders (thyroid disorder, hyperprolactinemia, congenital adrenal hyperplasia,
      androgen-secreting tumors, and Cushing's syndrome). The investigators included women aged
      between 18 and 38 years who were not: 1) pregnant, postpartum, breastfeeding, or 2) taking
      any vitamin D supplements, metformin or any hormonal therapy.

      Interventions and blood collection:

      68 women diagnosed with PCOS and vitamin D deficiency were enrolled. Participants were
      allocated to each group according to a computer-generated list using ratio 2/1 (Vitamin
      D/placebo). Women allocated to vitamin D group received one capsule 50.000 IU of vitamin D3
      once weekly for eight weeks. The vitamin D supplementation regimen was extracted from the
      Endocrine Society guidelines. Women in the placebo group received once capsule of placebo
      once weekly for eight weeks. The placebo was prepared at Maimonides Medical Center's
      pharmacy. To ensure compliance, The investigators called each participant once weekly and
      reminded her to take her pill. Fasting blood samples were collected by venipuncture before
      starting and within two weeks after completing the treatment (vitamin D or placebo). Blood
      samples were allowed to clot for 30 minutes at room temperature before centrifugation at
      1,200 rpm for 10 minutes. Serum was stored at -80°C in aliquots until assayed.

      The assays of all measured hormones, 25OH-D, VEGF, TGF-β1, sENG, and AMH:

      Serum 25OH-D levels were measured before and after completing the treatment. The levels were
      determined by the ADVIA Centaur vitamin D assay (Siemens Healthcare Diagnostics).
      Dehydroepiandrosterone sulfate (DHEAS), testosterone, sex hormone-binding globulin (SHBG),
      thyroid-stimulating hormone (TSH), follicle-stimulating hormone (FSH), and luteinizing
      hormone (LH) were measured using IMMULITE 2000 XPi immunoassay system (Siemens Healthcare
      USA). Insulin and prolactin concentrations were quantified by DXL 800 immunoassay analyzer
      according to manufacturer's protocols (Beckman Coulter). Insulin resistance was calculated
      according to the homeostatic model assessment (HOMA) (29) by using the following formula:
      Insulin resistance (HOMA IR) = [fasting insulin (µU/mL) x fasting glucose (mmol/L)]/22.5.
      17OH-progesterone level was determined by ELISA assay (Eagle BioSciences). AMH concentration
      was measured using the ultrasensitive AMH/MIS CLIA kit (AnshLabs). TGF-β1 concentration was
      measured using Human TGF-beta1 Quantikine ELISA kit according to manufacturer's protocols
      (R&amp;D Systems). sENG levels were quantified by Human Endoglin/CD105 Quantikine ELISA kit (R&amp;D
      Systems). VEGF concentration was quantified using Human VEGF Quantikine ELISA kit according
      to manufacturer's protocols (R&amp;D Systems). The inter-assay and intra-assay coefficients of
      variation for all assays were less than 10%.

      Clinical parameters:

      All the clinical parameters were evaluated before and four months after the completion of
      treatment. These parameters included blood pressure (BP), Ferriman-Gallwey score (FGS)
      (hirsutism score), acne status, and interval between periods.

      Statistical analysis:

      Data were tested for normality. All values were expressed as mean ± standard error of the
      mean (SEM). A paired student's t-test was used to compare pre- and post-treatment serum
      levels and clinical parameters. Correlation between changes in angiogenic factors and changes
      in clinical disease parameters was analyzed using Pearson's test and linear regression.
      X2-test was used to evaluate the changes in acne after treatment. SigmaStat (SPSS Science,
      Chicago, IL) was used for statistical analysis. P&lt;0.05 was considered to be statistically
      significant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Vitamin D on Angiogenic Factors</measure>
    <time_frame>Baseline (pre-treatment) and 8 weeks later (post-treatment)</time_frame>
    <description>Serum TGF-β1/sENG ratio as a measure of TGF-β1 bioavailability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Vitamin D on Angiogenic Factors</measure>
    <time_frame>Baseline (pre-treatment) and 8 weeks later (post-treatment)</time_frame>
    <description>Serum VEGF level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS</measure>
    <time_frame>Baseline (pre-treatment) and 4 months later (two months after the completion of treatment)</time_frame>
    <description>Interval between periods as a measure ovulatory dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS</measure>
    <time_frame>Baseline (pre-treatment) and 4 months later (two months after the completion of treatment)</time_frame>
    <description>Blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS</measure>
    <time_frame>Baseline (pre-treatment) and 8 weeks later (post-treatment)</time_frame>
    <description>The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance. Insulin resistance is a condition in which cells fail to respond to the normal actions of the hormone insulin. The HOMA index was calculated as the product of fasting plasma blood glucose and insulin divided by 22.5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS</measure>
    <time_frame>Baseline (pre-treatment) and 8 weeks later (post-treatment)</time_frame>
    <description>Free testosterone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS</measure>
    <time_frame>Baseline (pre-treatment) and 8 weeks later (post-treatment)</time_frame>
    <description>Lipid profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS</measure>
    <time_frame>Baseline (pre-treatment) and 4 months later (two months after the completion of treatment)</time_frame>
    <description>Ferriman-Gallwey score is a method used to assess and quantify hirsutism in women. A total score &lt; 8 is considered normal whereas a score of 8 to 15 indicates mild hirsutism. A score &gt;15 indicates moderate or severe hirsutism.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Vitamin D3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women allocated to vitamin D3 group received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Women in the placebo group received once capsule of placebo once weekly for eight weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Women allocated to vitamin D arm received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.</description>
    <arm_group_label>Vitamin D3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Women in the placebo arm received once capsule of placebo once weekly for eight weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with PCOS who have vitamin D deficiency (serum 25-hydroxyvitamin D&lt;20 ng/mL)

        Exclusion Criteria:

          -  Pregnant, postpartum, breast feeding

          -  Taking Metformin, vitamin D, or any hormonal therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>May 23, 2015</study_first_submitted>
  <study_first_submitted_qc>May 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <results_first_submitted>February 6, 2017</results_first_submitted>
  <results_first_submitted_qc>August 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2018</results_first_posted>
  <last_update_submitted>September 13, 2018</last_update_submitted>
  <last_update_submitted_qc>September 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maimonides Medical Center</investigator_affiliation>
    <investigator_full_name>Richard Grazi</investigator_full_name>
    <investigator_title>Director of Genesis Fertility and Reproductive Medicine, Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 93 women were screened for vitamin D deficiency. Sixty-eight women were diagnosed with vitamin D deficiency and were included in the study and randomly allocated into the two groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D3</title>
          <description>Women allocated to vitamin D3 group received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
Vitamin D3: Women allocated to vitamin D arm received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Women in the placebo group received once capsule of placebo once weekly for eight weeks.
Placebo: Women in the placebo arm received once capsule of placebo once weekly for eight weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D3</title>
          <description>Women allocated to vitamin D3 group received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
Vitamin D3: Women allocated to vitamin D arm received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Women in the placebo group received once capsule of placebo once weekly for eight weeks.
Placebo: Women in the placebo arm received once capsule of placebo once weekly for eight weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.5" spread="6.4"/>
                    <measurement group_id="B2" value="29.6" spread="7.6"/>
                    <measurement group_id="B3" value="30.2" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="45"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of Vitamin D on Angiogenic Factors</title>
        <description>Serum TGF-β1/sENG ratio as a measure of TGF-β1 bioavailability</description>
        <time_frame>Baseline (pre-treatment) and 8 weeks later (post-treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3</title>
            <description>Women allocated to vitamin D3 group received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
Vitamin D3: Women allocated to vitamin D arm received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Women in the placebo group received once capsule of placebo once weekly for eight weeks.
Placebo: Women in the placebo arm received once capsule of placebo once weekly for eight weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Vitamin D on Angiogenic Factors</title>
          <description>Serum TGF-β1/sENG ratio as a measure of TGF-β1 bioavailability</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum TGF-β1/sENG before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="0.4"/>
                    <measurement group_id="O2" value="5.6" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum TGF-β1/sENG after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="0.4"/>
                    <measurement group_id="O2" value="5.5" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of Vitamin D on Angiogenic Factors</title>
        <description>Serum VEGF level</description>
        <time_frame>Baseline (pre-treatment) and 8 weeks later (post-treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3</title>
            <description>Women allocated to vitamin D3 group received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
Vitamin D3: Women allocated to vitamin D arm received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Women in the placebo group received once capsule of placebo once weekly for eight weeks.
Placebo: Women in the placebo arm received once capsule of placebo once weekly for eight weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Vitamin D on Angiogenic Factors</title>
          <description>Serum VEGF level</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum VEGF level before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1106.4" spread="36.5"/>
                    <measurement group_id="O2" value="893.1" spread="90.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum VEGF level after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="965.3" spread="42.7"/>
                    <measurement group_id="O2" value="866" spread="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS</title>
        <description>Interval between periods as a measure ovulatory dysfunction</description>
        <time_frame>Baseline (pre-treatment) and 4 months later (two months after the completion of treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3</title>
            <description>Women allocated to vitamin D3 group received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
Vitamin D3: Women allocated to vitamin D arm received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Women in the placebo group received once capsule of placebo once weekly for eight weeks.
Placebo: Women in the placebo arm received once capsule of placebo once weekly for eight weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS</title>
          <description>Interval between periods as a measure ovulatory dysfunction</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Interval between periods before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2" spread="9.8"/>
                    <measurement group_id="O2" value="79" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval between periods after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="6.7"/>
                    <measurement group_id="O2" value="75" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS</title>
        <description>Blood pressure</description>
        <time_frame>Baseline (pre-treatment) and 4 months later (two months after the completion of treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3</title>
            <description>Women allocated to vitamin D3 group received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
Vitamin D3: Women allocated to vitamin D arm received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Women in the placebo group received once capsule of placebo once weekly for eight weeks.
Placebo: Women in the placebo arm received once capsule of placebo once weekly for eight weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS</title>
          <description>Blood pressure</description>
          <units>mmHG</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic blood pressure before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112" spread="1.9"/>
                    <measurement group_id="O2" value="113" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic blood pressure after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108" spread="1"/>
                    <measurement group_id="O2" value="109" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4" spread="1.1"/>
                    <measurement group_id="O2" value="69" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9" spread="1.3"/>
                    <measurement group_id="O2" value="67" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean arterial pressure before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" spread="1.2"/>
                    <measurement group_id="O2" value="84" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean arterial pressure after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" spread="1.1"/>
                    <measurement group_id="O2" value="81" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS</title>
        <description>The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance. Insulin resistance is a condition in which cells fail to respond to the normal actions of the hormone insulin. The HOMA index was calculated as the product of fasting plasma blood glucose and insulin divided by 22.5.</description>
        <time_frame>Baseline (pre-treatment) and 8 weeks later (post-treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 Group Before Treatment</title>
            <description>Women allocated to vitamin D3 group received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
Vitamin D3: Women allocated to vitamin D arm received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Women in the placebo group received once capsule of placebo once weekly for eight weeks.
Placebo: Women in the placebo arm received once capsule of placebo once weekly for eight weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS</title>
          <description>The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance. Insulin resistance is a condition in which cells fail to respond to the normal actions of the hormone insulin. The HOMA index was calculated as the product of fasting plasma blood glucose and insulin divided by 22.5.</description>
          <units>HOMA IR score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Insulin resistance (HOMA-IR)before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" spread="0.37"/>
                    <measurement group_id="O2" value="1.58" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insulin resistance (HOMA-IR) after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="0.22"/>
                    <measurement group_id="O2" value="1.52" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS</title>
        <description>Free testosterone</description>
        <time_frame>Baseline (pre-treatment) and 8 weeks later (post-treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3</title>
            <description>Women allocated to vitamin D3 group received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
Vitamin D3: Women allocated to vitamin D arm received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Women in the placebo group received once capsule of placebo once weekly for eight weeks.
Placebo: Women in the placebo arm received once capsule of placebo once weekly for eight weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS</title>
          <description>Free testosterone</description>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Free testosterone before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="0.06"/>
                    <measurement group_id="O2" value="0.61" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free testosterone after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.06"/>
                    <measurement group_id="O2" value="0.68" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS</title>
        <description>Lipid profile</description>
        <time_frame>Baseline (pre-treatment) and 8 weeks later (post-treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3</title>
            <description>Women allocated to vitamin D3 group received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
Vitamin D3: Women allocated to vitamin D arm received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Women in the placebo group received once capsule of placebo once weekly for eight weeks.
Placebo: Women in the placebo arm received once capsule of placebo once weekly for eight weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS</title>
          <description>Lipid profile</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HDL before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" spread="2.4"/>
                    <measurement group_id="O2" value="47" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" spread="2.6"/>
                    <measurement group_id="O2" value="50" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDH before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106" spread="6.1"/>
                    <measurement group_id="O2" value="103" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" spread="4.1"/>
                    <measurement group_id="O2" value="101" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total cholesterol before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183" spread="6.5"/>
                    <measurement group_id="O2" value="179" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total cholesterol after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166" spread="11"/>
                    <measurement group_id="O2" value="177" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138" spread="22"/>
                    <measurement group_id="O2" value="113" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117" spread="20"/>
                    <measurement group_id="O2" value="98" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS</title>
        <description>Ferriman-Gallwey score is a method used to assess and quantify hirsutism in women. A total score &lt; 8 is considered normal whereas a score of 8 to 15 indicates mild hirsutism. A score &gt;15 indicates moderate or severe hirsutism.</description>
        <time_frame>Baseline (pre-treatment) and 4 months later (two months after the completion of treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3</title>
            <description>Women allocated to vitamin D3 group received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
Vitamin D3: Women allocated to vitamin D arm received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Women in the placebo group received once capsule of placebo once weekly for eight weeks.
Placebo: Women in the placebo arm received once capsule of placebo once weekly for eight weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS</title>
          <description>Ferriman-Gallwey score is a method used to assess and quantify hirsutism in women. A total score &lt; 8 is considered normal whereas a score of 8 to 15 indicates mild hirsutism. A score &gt;15 indicates moderate or severe hirsutism.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ferriman-Gallwey score before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="1.5"/>
                    <measurement group_id="O2" value="8.1" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ferriman-Gallwey score after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="1.5"/>
                    <measurement group_id="O2" value="7.6" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D3</title>
          <description>Women allocated to vitamin D3 group received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
Vitamin D3: Women allocated to vitamin D arm received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Women in the placebo group received once capsule of placebo once weekly for eight weeks.
Placebo: Women in the placebo arm received once capsule of placebo once weekly for eight weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mohamad Irani</name_or_title>
      <organization>Maimonides Medical Center</organization>
      <phone>3472862167</phone>
      <email>mohamad.irani@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

